SEC Form 4 · accession 0001209191-18-051845

Odonate Therapeutics, Inc. · ODT

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owners

Kevin C Tang

Officer — Chief Executive Officer · Director · 10% Owner

TANG CAPITAL PARTNERS LP

10% Owner

TANG CAPITAL MANAGEMENT LLC

10% Owner

John G Lemkey

Officer — Chief Financial Officer

Period of report

Sep 18, 2018

Accepted (ET)

Sep 20, 2018 · 8:01 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001717452

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2	Sep 18, 2018	P	10,000	$19.3387	A	12,502,338	I	By LP
Common Stock^F3,F2	Sep 18, 2018	P	10,000	$19.3366	A	12,512,338	I	By LP
Common Stock^F4,F2	Sep 18, 2018	P	10,000	$19.029	A	12,522,338	I	By LP
Common Stock^F5,F2	Sep 18, 2018	P	10,000	$19.2982	A	12,532,338	I	By LP
Common Stock^F6,F2	Sep 18, 2018	P	10,000	$19.4161	A	12,542,338	I	By LP
Common Stock^F7,F2	Sep 19, 2018	P	10,000	$19.3086	A	12,552,338	I	By LP
Common Stock^F8,F2	Sep 19, 2018	P	2,017	$19.4783	A	12,554,355	I	By LP
Common Stock^F9,F2	Sep 20, 2018	P	7,983	$19.7521	A	12,562,338	I	By LP
Common Stock^F10,F2	Sep 20, 2018	P	10,000	$20.0788	A	12,572,338	I	By LP
Common Stock^F11,F2	Sep 20, 2018	P	10,000	$20.4267	A	12,582,338	I	By LP

Table II — derivative securities

No Table II lines on this filing.

Explanation of responses

F1The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $19.21 to $19.50. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC Staff, upon request, full information regarding the number of shares purchased at each price within the ranges set forth in footnotes 1 and 3 through 11 herein.
F10The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $19.86 to $20.24.
F11The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $20.22 to $20.50.
F2The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin C. Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. John G. Lemkey is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Operating Officer of TCM. Mr. Tang and Mr. Lemkey both have a pecuniary interest in a portion of the shares beneficially held by TCP.
F3The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $19.25 to $19.50.
F4The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $18.80 to $19.25.
F5The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $19.07 to $19.50.
F6The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $19.22 to $19.47.
F7The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $19.20 to $19.50.
F8The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $19.44 to $19.50.
F9The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $19.34 to $19.90.